Medigus Ltd. (TASE:MDGS) has notified the Tel Aviv Stock Exchange that it has successfully performed six additional procedures for treating Gastro Esophageal Reflex Disease (GERD) - a form of heartburn using the SRS endoscopic system that it has developed.

The procedures were performed as part of the company's multidisciplinary trials, which are one of the main requirements for the receipt of US Food and Drug Administration (FDA) approval. The company hopes to receive FDA marketing approval for its SRS system on the shortened 510K regulatory track.

The procedures were performed at the University of California at San Diego and were completed without serious adverse events.

In late afternoon trading, the company's share was up 2% to Nis 2.10.

Published by Globes [online], Israel business news - www.globes-online.com - on April 6, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010